Key Highlights

● Alphatec crashed on Friday, October 30, 2026, among the Russell 2000's heaviest losers.

● Third-quarter results missed expectations.

● It cut its Revenue outlook on lower Biologics attachment.

● Shares were sharply lower before the open.

Alphatec Holdings (NASDAQ:ATEC) was one of the heaviest losers on the Russell 2000 on Friday, October 30, 2026. The stock was already sharply lower before the open and the losses deepened through the day. Reports differed on the size of the decline at different times, but every reading showed a severe drop.

Alphatec, based in Carlsbad, California, develops technology for spine surgery, including implants, instruments, imaging and navigation systems, along with biologics, the bone-graft materials that surgeons use to help vertebrae fuse. When surgeons use Alphatec's biologics alongside its implants, the company earns more per procedure, which is what the industry calls attachment.

The quarter

Third-quarter revenue came in at $221.17 million, below the $225.44 million consensus, even though it rose from a year earlier. Adjusted Earnings were $0.09 a share, one cent short of the $0.10 analysts expected.

The outlook was the bigger blow. Alphatec cut its full-year revenue guidance to about $862 million from about $882 million and now expects biologics to be flat. Chief executive Pat Miles said, "third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment."

Analysts trimmed their targets after the report. Needham cut its price target to $12 from $14, TD Cowen lowered its target to $10 from $13, and Stifel (NYSE:SF) reduced its target to $11 from $13, according to market data. All three firms lowered their targets following the reduced guidance.

Medtech's mixed day

Alphatec's slide stood out on a day when health care was one of the market's strongest sectors, hitting a record high according to market data. But the gains were uneven. Stryker (NYSE:SYK) also fell after cutting its organic growth outlook, with Canaccord downgrading the shares and citing a slowdown in hip and knee markets. Illumina (NASDAQ:ILMN) dropped after revenue fell short. Meanwhile, DexCom rose after beating estimates and Regeneron (NASDAQ:REGN) jumped to the top of the S&P 500.

The contrast suggested investors were sorting health care companies on their own results rather than buying the sector wholesale.

The broader market

Overall, it was Wall Street's worst day since June. The S&P 500 fell 140.32 points to 7,580.07, the Dow lost 572.25 points to 51,770.31 and the Nasdaq Composite tumbled 747.73 points to 25,437.00. The Russell 2000 declined 47.37 points to 2,811.84, though small caps still finished the week higher.

Intel (NASDAQ:INTC)'s weak outlook and warning about cash burn set off a rout in chip stocks, and Amazon (NASDAQ:AMZN)'s results deepened concerns about AI spending. The number of stocks hitting 52-week lows jumped to 448 from 230 on Thursday, while only 162 set new highs.

The Federal Reserve held its benchmark rate range steady this week, but futures markets were pricing a December hike as likely, and several Fed officials argued on Friday for tighter policy.

What to watch

For Alphatec, the key question is whether biologics attachment recovers and whether the company can meet its lowered revenue target of about $862 million. Investors will look for more detail on surgeon adoption and procedure volumes, and on the company's plans for its biologics business.

Peer results and commentary on spine and orthopedic procedure trends will also matter, especially after Stryker's comments on a hip and knee slowdown. The October jobs report on Friday, Nov. 6, and the midterm elections on Tuesday, Nov. 3, will shape the broader market backdrop.